Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption

The Aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe

(2011) Yungan Tao et al.   CELL CYCLE

Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC

(2010) Zhong-Zhe Lin et al.   BMC CANCER

Multimodal approaches to the treatment of hepatocellular carcinoma

(2009) Giuseppe Cabibbo et al.   Nature Reviews Gastroenterology & Hepatology

Radiotherapy for Hepatocellular Carcinoma: An Overview

(2008) Sunil Krishnan et al.   ANNALS OF SURGICAL ONCOLOGY

Aurora Kinases as Anticancer Drug Targets

(2008) O. Gautschi et al.   CLINICAL CANCER RESEARCH

The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma

(2008) Zhong-Zhe Lin et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE